Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCA for Refractory/Relapsed AML
NCT05305859Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Complete Remission Rate at 2 months and Overall Response Rate at 2 months. Started Jan 2022; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05305859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305859.